The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.
 
Annick Desjardins
Stock and Other Ownership Interests - ISTARI Oncology
Consulting or Advisory Role - Celgene; Genentech/Roche
Research Funding - Celldex (Inst); Genentech/Roche (Inst); Lilly (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); Symphogen (Inst); Triphase Accelerator Corp (Inst)
Patents, Royalties, Other Intellectual Property - AU 2013347945 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; CA 2,892,183 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; CN 201380070749.7 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; EP 13856989.2 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; HK 15112399.5 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; JP 2015-544130 Div: 2017-084158 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, and a patent; PCT/US17/023148 - Combination Therapy for Cancer Using Oncolytic Poliovirus licensed to Istari and Stock options, ISTARI Oncology; US 15/428510 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent
 
Matthias Gromeier
Stock and Other Ownership Interests - ISTARI Oncology
Patents, Royalties, Other Intellectual Property - Activation of Dendritic Cells with PVSRIPO PCT/US17/039953; Combination Therapy for Cancer Using Oncolytic Poliovirus PCT/US17/023148; Enterovirus-IRES Insertion Expression Vector US 7,968,086; Method of Treating Solid Tumor w/ Oncolytic Poliovirus AU2013347945; Method of Treating Solid Tumor w/ Oncolytic Poliovirus CA 2,892,183; Method of Treating Solid Tumor w/ Oncolytic Poliovirus CN201380070749.7; Method of Treating Solid Tumor w/ Oncolytic Poliovirus EP 13856989.2; Method of Treating Solid Tumor w/ Oncolytic Poliovirus HK 15112399.5; Method of Treating Solid Tumor w/ Oncolytic Poliovirus JP 2015-544130; Method of Treating Solid Tumor w/ Oncolytic Poliovirus US 15/428510; PVSRIPO-Checkpoint Inhibitor Combination Therapy PCT/US16/057023
 
James Emmett Herndon
No Relationships to Disclose
 
Dina Randazzo
Consulting or Advisory Role - Optune
 
Stevie Threatt
No Relationships to Disclose
 
Eric S. Lipp
No Relationships to Disclose
 
Elizabeth S. Miller
No Relationships to Disclose
 
Jennifer Jackman
No Relationships to Disclose
 
Dani P. Bolognesi
Employment - ISTARI Oncology
Stock and Other Ownership Interests - ISTARI Oncology
 
Allan H. Friedman
Stock and Other Ownership Interests - ISTARI Oncology
 
Henry S. Friedman
Leadership - Istari Oncology
Stock and Other Ownership Interests - 2x Oncology; ISTARI Oncology
Honoraria - Genentech/Roche
Consulting or Advisory Role - Genentech/Roche
Speakers' Bureau - Genentech/Roche
Patents, Royalties, Other Intellectual Property - Letters of Patent for Oncolytic Poliovirus for Human Tumors
Travel, Accommodations, Expenses - Genentech/Roche
 
Frances McSherry
No Relationships to Disclose
 
Katherine B. Peters
Consulting or Advisory Role - Abbvie; Agios; Boehringer Ingelheim; Eisai; Monteris Medical; Novocure
Research Funding - Abbvie; Agios; BioMimetix; Bristol-Myers Squibb; Monteris Medical
 
Margaret O Johnson
No Relationships to Disclose
 
John H. Sampson
Stock and Other Ownership Interests - Annias Immunotherapeutics; Immunomic Therapeutics; Insera Health; ISTARI; Neuronium
Honoraria - National Cancer Institute
Consulting or Advisory Role - Annias Immunotherapeutics; Bristol-Myers Squibb; Insera Health; Insera Health; Medicenna
Patents, Royalties, Other Intellectual Property - Annias Immunotherapeutics - Equity, Licensed IP; Celldex - Licensed IP, Royalties; Istari Oncology - Equity, Licensed IP; Neuronium - Equity, Optioned IP
 
David M. Ashley
Patents, Royalties, Other Intellectual Property - Methods for predicting tumor response to immunotherapy, U.S. Provisional application no. 62/787,508 filed January 2, 2019 Methods for predicting tumor response to immunotherapy, U.S. Provisional application no. 62/620,577 filed January 23, 2018
Expert Testimony - Tanoury, Nauts, McKinney & Garbarino, PLLC
 
Darell D. Bigner
Stock and Other Ownership Interests - ISTARI Oncology
Patents, Royalties, Other Intellectual Property - ISTARI Oncology